Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Post time 2024-4-21 18:59:03

journal：Journal of Clinical Oncology

Authors：Claire N. Harrison; Jyoti Nangalia; Rebecca Boucher; Aimee Jackson; Christina Yap; Jennifer O'Sullivan; Sonia Fox; Isaak Ailts; Amylou C. Dueck; Holly L. Geyer; Ruben A. Mesa; William G. Dunn; Eugene Nadezhdin; Natalia Curto-Garcia; Anna Green; Bridget Wilkins; Jason Coppell; John Laurie; Mamta Garg; Joanne Ewing; Steven Knapper; Josephine Crowe; Frederick Chen; Ioannis Koutsavlis; Anna Godfrey; Siamak Arami; Mark Drummond; Jennifer Byrne; Fiona Clark; Carolyn Mead-Harvey; Elizabeth Joanna Baxter; Mary Frances McMullin; Adam J. Mead

Published date：2023-7-1

DOI：10.1200/jco.22.01935

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.01935

Article link：http://dx.doi.org/10.1200/jco.22.01935

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time 2024-4-21 18:59:04

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial